Prosecution Insights
Prosecution Insights
2 pending office actions • 0 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Viking Therapeutics Inc. is currently overseeing 2 pending office actions, which are being handled by 2 distinct examiners. This indicates that each of the company's active matters is under the review of a different individual at the patent office. The busiest examiner for the portfolio is WHITE, DAWANNA SHAR-DAY, who is currently managing 1 pending office action. Interestingly, the data shows 0 distinct art units for the current active portfolio.
With 2 pending office actions and 2 distinct examiners involved, the company's prosecution strategy is split between two different reviewers. This distribution means that the company must manage two separate sets of feedback and examination styles. However, the 0 distinct art units reported indicate a lack of technical classification diversity in the current active portfolio. Practitioners should focus on the individual requirements of each examiner, including WHITE, DAWANNA SHAR-DAY, to successfully resolve these 2 pending actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836719 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | AGGARWAL, SAHIL CHANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836713 | POLYMORPHIC FORMS AND METHODS OF PRODUCING POLYMORPHIC FORMS OF A COMPOUND | WHITE, DAWANNA SHAR-DAY | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836719 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME | AGGARWAL, SAHIL CHANDER | — | §102§103§112DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18836713 | POLYMORPHIC FORMS AND METHODS OF PRODUCING POLYMORPHIC FORMS OF A COMPOUND | WHITE, DAWANNA SHAR-DAY | — | §103DP | Non-Final OA | — | Pending | Aug 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial